Elite in Dry Mouth

Sandrine Joulin-Jousse

CHU De Brest
Brest, FR 
Elite in Dry Mouth
CHU De Brest
Brest, FR 
OverviewLocationsClinical Research

Overview

Sandrine Joulin-Jousse practices in Brest, France. Ms. Joulin-Jousse is rated as an Elite expert by MediFind in the treatment of Dry Mouth. Her top areas of expertise are Dry Mouth, Sjogren Syndrome, Dry Eye Syndrome, and Synovitis.

Her clinical research consists of co-authoring 132 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 48 articles in the study of Dry Mouth.

Gender
Female

Locations

CHU de Brest
Brest, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

ULnar Nerve ECHographic Observation (ULNECHO)
ULnar Nerve ECHographic Observation (ULNECHO)
Enrollment Status: Completed
Publish Date: December 03, 2025
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
A Follow-up Phase 2a Open-label Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 in Patients With Moderate to Severe Active Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: November 17, 2025
Intervention Type: Drug
Study Drug: ABX464
Study Phase: Phase 2
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Completed
Publish Date: February 18, 2025
Intervention Type: Drug
Study Drugs: Rituximab, Standard therapy (Including Immunosuppressants), Standard therapy (Excluding Immunosuppressants), Steroid Taper
Study Phase: Phase 3
Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment
Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Phase IIa Randomized, Double Blind, Placebo Controlled, Multiple Dose Study on ABX464 in Combination With Methotrexate (MTX), in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have Inadequate Response to MTX or/and to Anti-Tnfα, or Intolerance to Anti-Tnfα
Enrollment Status: Completed
Publish Date: February 15, 2023
Intervention Type: Drug
Study Drugs: ABX464, Methotrexate
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 23, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 6 Less Clinical Trials

132 Total Publications

Advances in imaging techniques for Sjogren's disease.
Advances in imaging techniques for Sjogren's disease.
Journal: Best practice & research. Clinical rheumatology
Published: May 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Joulin-Jousse's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile